{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:16:43Z","timestamp":1784809003408,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: The COVID-19 pandemic was characterized by mild-to-moderate disease in children and adolescents, with low incidences of severe cases and mortality. Most of the information on drug therapy in COVID-19-positive children was derived from research in adult patients. Remdesivir, an inhibitor of viral RNA polymerase, was shown to be effective in COVID-19 patients with moderate-to-severe disease. In this study, we present our experience of the use of remdesivir in pediatric patients hospitalized with COVID-19. Materials and methods: This retrospective study was based on the early use of remdesivir in 14 children with mild, moderate, and severe clinical forms of COVID-19, who were hospitalized between 1 January 2022, and 30 September 2023. Results: The patients included eight infants and six children older than 1 day (the age range was 2 months to 17 years). Most of them (92.85%) had documented pneumonia. Four patients had associated acute laryngitis, and another had bronchiolitis. Coinfections with Streptococcus pneumoniae were diagnosed in two patients. The clinical course was favorable in 12\/14 (85.71%) children. Two patients were transferred to the pediatric intensive care unit because of aggravation of associated acute diseases (acute laryngitis and bronchiolitis, respectively). Mild increases in alanine aminotransferase levels occurred in two patients, with no increase in serum creatinine, during treatment with remdesivir. Conclusion: The appropriate use of remdesivir proved safe and efficient in our group of patients. However, further studies are required to support the efficiency, tolerability, and safety of remdesivir in children.<\/jats:p>","DOI":"10.3390\/life14030410","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:56:07Z","timestamp":1710914167000},"page":"410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment with Remdesivir of Children with SARS-CoV-2 Infection: Experience from a Clinical Hospital in Romania"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-6600","authenticated-orcid":false,"given":"Maria-Elena","family":"Cocuz","sequence":"first","affiliation":[{"name":"Fundamental Prophylactic and Clinical Disciplines Department, Faculty of Medicine, Transilvania University of Brasov, 500003 Brasov, Romania"},{"name":"Clinical Pneumology and Infectious Diseases Hospital of Brasov, 500118 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-2433","authenticated-orcid":false,"given":"Iuliu Gabriel","family":"Cocuz","sequence":"additional","affiliation":[{"name":"Pathophysiology Department, \u201cGeorge Emil Palade\u201d University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania"},{"name":"Pathology Department, Mures Clinical County Hospital, 540011 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia","family":"Rodina","sequence":"additional","affiliation":[{"name":"Clinical Pneumology and Infectious Diseases Hospital of Brasov, 500118 Brasov, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tataranu","sequence":"additional","affiliation":[{"name":"Clinical Department of Pediatrics, \u201cSf. Ioan cel Nou\u201d Emergency Hospital, 720224 Suceava, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-6439","authenticated-orcid":false,"given":"Olga Adriana","family":"Caliman-Sturdza","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cSf. Ioan cel Nou\u201d Emergency Hospital, 720224 Suceava, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-2565","authenticated-orcid":false,"given":"Florin","family":"Filip","sequence":"additional","affiliation":[{"name":"\u201cSf. Ioan cel Nou\u201d Emergency Hospital, 720224 Suceava, Romania"},{"name":"Faculty of Medicine and Biological Sciences, Stefan cel Mare University of Suceava, 720229 Suceava, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3345\/cep.2022.00458","article-title":"Therapeutics for the Treatment of Coronavirus Disease 2019 in Children and Adolescents","volume":"65","author":"Choi","year":"2022","journal-title":"Clin. Exp. Pediatr. Online"},{"key":"ref_2","first-page":"255","article-title":"Clinical Care of Children and Adolescents with COVID-19: Recommendations from the National COVID-19 Clinical Evidence Taskforce","volume":"216","author":"Tendal","year":"2021","journal-title":"Med. J. Aust."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.3346\/jkms.2022.37.e13","article-title":"Analysis of Critical COVID-19 Cases among Children in Korea","volume":"37","author":"Lee","year":"2022","journal-title":"J. Korean Med. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2021053418","DOI":"10.1542\/peds.2021-053418","article-title":"Risk Factors for Severe COVID-19 in Children","volume":"149","author":"Woodruff","year":"2021","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2111182","DOI":"10.1001\/jamanetworkopen.2021.11182","article-title":"Underlying Medical Conditions Associated with Severe COVID-19 Illness among Children","volume":"4","author":"Kompaniyets","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/TCRM.S432565","article-title":"Efficacy and Safety of Remdesivir in Hospitalized Pediatric COVID-19: A Retrospective Case-Controlled Study","volume":"19","author":"Khalil","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/jpids\/piaa098","article-title":"Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute COVID-19 in Pediatric Patients","volume":"9","author":"Dulek","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_8","unstructured":"National Institute for Health and Care Excellence (2021). COVID-19 Rapid Guideline: Managing COVID-19 [Internet], NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ng191\/chapter\/Recommendations."},{"key":"ref_9","unstructured":"(2023, October 18). Information on COVID-19 Treatment, Prevention and Research, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"ref_10","unstructured":"World Health Organization (2023, October 16). Therapeutics and COVID-19: Living Guideline [Internet], Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.3."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiab305","article-title":"Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit","volume":"224","author":"Hall","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/INF.0000000000003814","article-title":"Remdesivir Use in Pediatric Patients for SARS-CoV-2 Treatment: Single Academic Center Study","volume":"42","author":"Samuel","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jpids\/piaa115","article-title":"Multicenter Interim Guidance on Use of Antivirals for Children with COVID-19\/SARS-CoV-2","volume":"10","author":"Chiotos","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_14","unstructured":"(2023, October 18). FDA Approves First Treatment for COVID-19, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref_15","unstructured":"(2023, October 18). Elena Kostadinova DIMITROVA Veklury\u2014European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veklury."},{"key":"ref_16","unstructured":"Korea Disease Control and Prevention Agency (2023, October 18). Guidance on the Use of COVID-19 Treatment [Internet], Available online: https:\/\/www.kdca.go.kr\/board\/board.es?mid=a20507020000&bid=0019&act=view&list_no=719252."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19\u2014Preliminary Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious Bradycardia and Remdesivir for Coronavirus 2019 (COVID-19): A New Safety Concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00431-023-05287-4","article-title":"Evaluation of the Safety Profile and Therapeutic Efficacy of Remdesivir in Children with SARS-CoV-2 Infection\u2014A Single-Center, Retrospective, Cohort Study","volume":"183","author":"Kautsch","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"ref_20","unstructured":"(2023, October 18). Treatment Protocol for Infection with SARS-CoV-2 Virus\u2014January 2022 (Order of the Ministry of Health\u2014Romania). Available online: https:\/\/legislatie.just.ro\/Public\/DetaliiDocument\/250463."},{"key":"ref_21","unstructured":"(2023, December 16). Treatment Protocol for Infection with SARS-CoV-2 Virus\u2014June 2022 (Order of the Ministry of Health\u2014Romania). Available online: https:\/\/lege5.ro\/gratuit\/geztonzzgq3ts\/protocolul-de-tratament-al-infectiei-cu-virusul-sars-cov-2-din-22062023."},{"key":"ref_22","unstructured":"(2023, October 18). Veklury (Remdesivir) an Overview of Veklury and Why It Is Authorised in the EU. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/veklury-epar-medicine-overview_en.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in Favour of Remdesivir for Treating SARS-CoV-2 Infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","first-page":"1326","article-title":"COVID-19 and Remdesivir in Pediatric Patients: The Invisible Part of the Iceberg","volume":"89","author":"Demirkan","year":"2020","journal-title":"Pediatr. Res."},{"key":"ref_25","first-page":"171","article-title":"First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease","volume":"215","author":"Burzio","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_26","unstructured":"(2023, October 18). Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734TM), Available online: https:\/\/www.fda.gov\/media\/137566\/download."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hussain Alsayed, H.A., Saheb Sharif-Askari, F., Saheb Sharif-Askari, N., Hussain, A.A.S., Hamid, Q., and Halwani, R. (2021). Early Administration of Remdesivir to COVID-19 Patients Associates with Higher Recovery Rate and Lower Need for ICU Admission: A Retrospective Cohort Study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0258643"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2020047803","DOI":"10.1542\/peds.2020-047803","article-title":"Compassionate Use of Remdesivir in Children with Severe COVID-19","volume":"147","author":"Goldman","year":"2021","journal-title":"Pediatrics"},{"key":"ref_29","first-page":"1317","article-title":"Compassionate Use of Remdesivir in Children with COVID-19","volume":"180","author":"Ara","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"ref_30","unstructured":"Tessa, A., Motisi, M., Marseglia, G., Cardinale, F., Licari, A., Manti, S., Tosca, M., Miraglia, M., Giudice, D., and De Filippo, M. (2021). Use of Remdesivir in Children with COVID-19 Infection: A Quick Narrative Review. Acta Biomed., 92."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/piab123","article-title":"A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020","volume":"11","author":"Schuster","year":"2022","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_32","unstructured":"(2023, October 18). Gilead Sciences A Phase 2\/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734TM) in Participants from Birth to <18 Years of Age with COVID-19, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04431453."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients","volume":"386","author":"Gottlieb","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jugulete, G., Luminos, M., Pavelescu, C., and Meri\u0219escu, M.M. (2023). Remdesivir Efficacy and Tolerability in Children with COVID-19-Associated Allergic Comorbidities such as Asthma, Allergic Rhinitis, and Atopic Dermatitis. Children, 10.","DOI":"10.3390\/children10050810"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102816","DOI":"10.1016\/j.amsu.2021.102816","article-title":"Lymphopenia in COVID-19: A Single Center Retrospective Study of 589 Cases","volume":"69","author":"Ghizlane","year":"2021","journal-title":"Ann. Med. Surg."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/410\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:16:30Z","timestamp":1760105790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/3\/410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["life14030410"],"URL":"https:\/\/doi.org\/10.3390\/life14030410","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}